Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...

Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.

Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. About Tempus Tempus is a ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

On February 3 rd, the company announced that it had completed its acquisition of Ambry Genetics, a genetic testing company that strives to improve health by understanding the relationship between ...

Shares of Tempus AI , Inc. (NASDAQ:TEM) climbed 5% in pre-open trading Tuesday following the completion of its acquisition of ...

Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market share gains following Invitae’s bankruptcy.

Tempus AI Inc. (NASDAQ:TEM) grew its share prices by 7.23 percent on Monday to end at $61.54 apiece as investor sentiment was ...

TD Cowen reinitiated coverage on Tempus AI Inc (NASDAQ:TEM) with a Buy rating, increasing the price target to $74 from a previous target. The stock, currently trading at $61.85, has shown remarkable ...

Preliminary Q4 results and 2025 guidance show mixed performance, with revenue slightly below expectations but positive adjusted EBITDA anticipated for 2025, driven by the Ambry Genetics acquisition.